Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol ID
AALL1732
Disease (Sub Disease)
Leukaemia (ALL)
Diagnosis Stage
New Diagnosis
Location
NSW, QLD, VIC, SA, NZ
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
Trial Status
Open
Sites
John Hunter Children's Hospital
Monash Children's Hospital
Queensland Children's Hospital
Women's & Children's Hospital
Christchurch Hospital
Starship Hospital
Study Type
Treatment
Phase
Phase 3
Age Eligibility
1 Year to 24 Years
International registry ID's
NCT03959085
Back to Registry
Study Title A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL Mixed Phenotype Acute Leukemia and Disseminated B-LLy
Protocol ID AALL1732
Disease (Sub Disease) Leukaemia (ALL)
Diagnosis Stage New Diagnosis
Location NSW / QLD / VIC / SA / NZ
Sponsor Children's Oncology Group
Collaborators National Cancer Institute (NCI)
Links https://clinicaltrials.gov/ct2/show/NCT03959085
Trial Status Open
Trial Open Date 28/10/2019
Sites John Hunter Children's Hospital / Monash Children's Hospital / Queensland Children's Hospital / Women's & Children's Hospital / Christchurch Hospital / Starship Hospital
Study Type Treatment
Phase Phase 3
Age Eligibility 1 Year to 24 Years
International registry ID's NCT03959085